CorMedix Inc

NASDAQ:CRMD   3:59:54 PM EDT
3.10
-0.08 (-2.52%)
Products

CorMedix Announces FDA Acceptance Of Resubmission Of NDA For DefenCath

Published: 03/28/2022 12:50 GMT
CorMedix Inc (CRMD) - Cormedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for Defencath.
Cormedix Inc - FDA Considers Resubmission As a Complete, Class 2 Response With a Six Month Review Cycle.